Научно-практическая ревматология (Apr 2012)

New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol

  • Dmitry Evgenyevich Karateev,
  • E L Nasonov,
  • L N Denisov,
  • M L Stanislav,
  • E Yu Panasyuk,
  • I A Andrianova,
  • V I Mazurov,
  • E S Zhugrova,
  • Yu P Uspensky,
  • L N Belousova,
  • E P Ilivanova,
  • G K Matsiyevskaya,
  • G P Aurtyunov,
  • K A Lytkina,
  • R S Saikovsky,
  • V N Ardashev,
  • E V Zhilyaev,
  • N I Korshunov

DOI
https://doi.org/10.14412/1995-4484-2012-1267
Journal volume & issue
Vol. 50, no. 2
pp. 14 – 19

Abstract

Read online

Certolizumab pegol (CZP) is a new drug from the group of tumor necrosis factor a inhibitors. The efficacy and safety CZP in the treatment of rheumatoid arthritis (RA) have been studied in the international 52-week RAPID-1 and 24-week RAPID-2 clinical trials that studied the use of CZP in combination with methotrexate (MTX) in patients with active RA unresponsive to MTX. The study populations of the RAPID 1 and RAPID 2 trials constituted the major portion of Russian patients (11.8 and 18.4%, respectively), including that in the prolonged open-labeled phases. The results of using CZP in Russian patients in the RAPID trials showed that they displayed a highly stable response to treatment and a rapidly developing clinical effect, that a therapy response could be predicted in the first 12 weeks, and that the incidence of local postinjection reactions was low.

Keywords